TMCnet News

RIGEL PHARMACEUTICALS INC FILES (8-K) Disclosing Change in Directors or Principal Officers
[March 05, 2014]

RIGEL PHARMACEUTICALS INC FILES (8-K) Disclosing Change in Directors or Principal Officers


(Edgar Glimpses Via Acquire Media NewsEdge) Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) At a meeting of the Compensation Committee of the Board of Directors of Rigel Pharmaceuticals, Inc. (the "Company") held on February 27, 2014, the Compensation Committee approved stock option grants to certain of the Company's officers (collectively, the "Officers"): Name Title Stock Options James Grower Chief Executive Officer 500,000 Donald Payan Executive Vice President, President of Discovery and Research 300,000 Raul Rodriguez President and Chief Operating Officer 300,000 Elliott Grossbard Executive Vice President, Chief Medical Officer 300,000 Ryan Maynard Executive Vice President, Chief Financial Officer 250,000 Dolly Vance Executive Vice President, Corporate Affairs, General Counsel and Secretary 250,000 The stock options shall vest as follows: 50% of the shares of common stock subject to the award shall vest in equal monthly installments over four years from the vesting commencement date of January 1, 2014; and 50% of the shares of common stock subject to the award shall vest based on the achievement of one or more performance conditions. The committee did not approve any changes to the salaries of the Officers from 2013 levels and no payouts were made under the 2013 Cash Incentive Plan.



2 --------------------------------------------------------------------------------

[ Back To TMCnet.com's Homepage ]